• 中国核心期刊(遴选)数据库收录期刊
  • 中文科技期刊数据库收录期刊
  • 中国期刊全文数据库收录期刊
  • 中国学术期刊综合评价数据库统计源期刊等

中国药物评价 ›› 2023, Vol. 40 ›› Issue (5): 435-438.

• 药品评价 • 上一篇    下一篇

布地奈德联合异丙托溴铵溶液雾化治疗对慢性支气管炎患者肺功能、血气分析及Th1/Th2细胞因子的影响

田金亚, 段小凯, 樊实真   

  1. 郑州市第一人民医院, 河南 郑州 450000
  • 收稿日期:2023-06-30 修回日期:2023-07-10 出版日期:2023-10-28 发布日期:2023-10-28

Effects of Budesonide combined with Ipratropium Bromide Solution on Lung Function, Blood Gas Analysis and Th1/Th2 Cytokines with Chronic Bronchitis

  1. Zhengzhou First People′s Hospital, Henan Zhengzhou 450000, China
  • Received:2023-06-30 Revised:2023-07-10 Online:2023-10-28 Published:2023-10-28

摘要: 目的:探讨布地奈德与异丙托溴铵溶液联合治疗对慢性支气管炎(CB)患者肺功能、血气分析及Th1/Th2细胞因子的影响。方法:依随机数字表法将我院2021年6月至2023年5月收治的150例CB患者分为参照组(75例)、联合组(75例)。两组在常规治疗的同时,参照组予以布地奈德治疗,联合组予以布地奈德+异丙托溴铵溶液联合氧气驱动雾化治疗。比较两组疗效、治疗前后肺功能[第1s用力呼气量(FEV1)、最大呼气峰流速(PEF)、FEV1/用力肺活量(FEV1/FVC)]、血气分析指标[血氧饱和度(SpO2)、二氧化碳分压(PaCO2)]、Th1/Th2细胞因子[白介素-2(IL-2)、IL-5、IL-13、γ-干扰素(IFN-γ)]、Treg细胞比率及转录因子FOXP3。结果:联合组总有效率(97.33%)高于参照组(85.33%)(P<0.05);治疗后,联合组FEV1、PEF、FEV1/FVC、SpO2均高于参照组,PaCO2低于参照组(P<0.05);联合组IL-2、IFN-γ水平高于参照组,IL-5、IL-13水平低于参照组(P<0.05);联合组Treg细胞比率、FOXP3表达高于参照组(P<0.05);联合组不良反应总发生率(9.34%)与参照组(8.00%)相比,无明显差异(P>0.05)。结论:布地奈德与异丙托溴铵溶液联合用氧气驱动雾化治疗CB疗效确切,可减轻炎症,提高机体免疫,改善血气分析指标、肺功能,利于病情恢复,且用药较安全可靠。

关键词: font-size:medium, ">慢性支气管炎;异丙托溴铵溶液;布地奈德;肺功能;疗效

Abstract: Objective: To investigate the effects of combination therapy with budesonide and ipratropium bromide solution on lung function, blood gas analysis and Th1/Th2 cytokines in patients with chronic bronchitis (CB). Methods: 150 CB patients admitted to our hospital from June 2021 to May 2023 were divided into a reference group (75 patients) and a combination group (75 patients) according to the random number table method. The reference group was treated with budesonide and the combination group was treated with budesonide+ipratropium bromide solution combined with oxygen-driven nebulization. The efficacy, pulmonary function [1sts expiratory volume (FEV1), peak expiratory flow rate (PEF), FEV1/Forced lung volume (FEV1/FVC)], blood gas analysis indexes [oxygen saturation (SpO2), partial pressure of carbon dioxide (PaCO2)], Th1/Th2 cytokines [interleukin-2 (IL-2), IL-5, IL-13, gamma-interferon (GI)] were compared between the two groups.-13, gamma-interferon (IFN-γ)], Treg cell ratio and transcription factor FOXP3. Results: The total effective rate of the combined group (97.33%) was higher than that of the reference group (85.33%) (P<0.05). After treatment, FEV1, PEF, FEV1/FVC and SpO2 in combination group were higher than those in reference group, and PaCO2 was lower than that in reference group (P<0.05). The levels of IL-2 and IFN-γ in combination group were higher than those in reference group, and the levels of IL-5 and IL-13 were lower than those in reference group (P<0.05). Treg cell ratio and FOXP3 expression in combination group were higher than those in reference group (P<0.05). There was no significant difference in the total incidence of adverse reactions between the combined group (9.34%) and the reference group (8.00%) (P>0.05). Conclusion: The combination of budesonide and ipratropium bromide solution with oxygen driven atomization is effective in the treatment of CB, which can improve immunity, reduce inflammation, improve lung function and blood gas analysis index, and is conducive to disease recovery, and the drug is safe and reliable.

Key words: font-size:medium, ">Chronic bronchitis; Ipratropium bromide solution; Budesonide; Lung function; Curative effect

中图分类号: